On 21 August 2019, orphan designation EU/3/19/2190 was granted by the European Commission to Eiger Biopharmaceuticals Europe Limited, United Kingdom, for peginterferon lambda-1a for the treatment of hepatitis D virus infection.
The sponsorship was transferred to Eigerbio Europe Limited, Ireland, in October 2019.
Treatment of hepatitis D virus infection
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: